LifeCord

growth-positive

LifeCord, a company specializing in innovative mitral chordal repair solutions, has raised $1.3 million in a seed investment round. The funding will be used to advance their minimally invasive transcatheter system for treating degenerative mitral regurgitation (DMR), a condition affecting a significant portion of the population. LifeCords device offers a safer alternative to open-heart surgery, preserving the mitral leaflet and allowing for future interventions. The company is backed by a strong intellectual property portfolio and strategic partnerships with MEDX Xelerator, a multinational medical device corporation, and a U.S. healthcare institution. The funds will support the completion of First-in-Human trials and further R&D efforts, positioning LifeCord as a key player in the $2 billion mitral valve intervention market.